Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
What Lupin files
- Updates148
- Others107
- Investor Meet34
- Important19
- PPTs8
- Board Meeting8
**1. Business Performance:** Lupin reported a strong Q1 FY27: sales up 33% YoY to ₹8,217.2 Cr. Net Income grew 16% to ₹1,415 Cr, and EBITDA surged 50% YoY to ₹2,463.5 Cr, achieving a healthy 30% margin. North America sales jumped 43% (US at $366 Mn), and India's business grew 14%,...
Lupin reported robust Q1 FY27 results, with sales growing 33% YoY to ₹8,217.2 Cr. Net Income rose 16% YoY to ₹1,415.0 Cr, and EBITDA jumped 50% YoY to ₹2,463.5 Cr, pushing margins to 30.0%. Growth was strong across most geographies, especially North America (up 43% YoY to ₹3,590.8 Cr) and...
Lupin delivered a strong Q4 FY26! Sales hit ₹7,391.9 Cr, up 33% YoY. EBITDA soared 89% to ₹2,171.1 Cr, with margins at 29.4%. Net Income grew 68% to ₹1,460.4 Cr, boosted by one-time exceptional items. North America sales jumped 55% YoY to ₹3,514.5 Cr ($37.1 Cr), while India business grew...
Lupin delivered a strong Q2 FY26. Sales surged 24% YoY to ₹6,831.4 Cr, while Net Income soared 73% to ₹1,477.9 Cr. EBITDA jumped 63% to ₹2,137.6 Cr, pushing margins to 31.3%. Growth was significantly fueled by North America (+46% YoY) and LATAM (+81% YoY). The company is strategically focused on...
Here's a summary of Lupin Limited's Q1 FY26 results: **1. Financial Highlights:** Lupin delivered strong Q1 FY26: Sales up 12% YoY to ₹6,163.8 Cr. EBITDA surged 52% to ₹1,641.4 Cr (26.6% margin), Net Income grew 28% to ₹1,219.1 Cr. US sales reached $282 Mn (+22% YoY), India sales ₹2,089.4 Cr...